SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation announced the exercise of certain outstanding common stock purchase warrants, resulting in approximately $3.3 million in gross proceeds. The company entered into definitive agreements to allow holders to exercise warrants at a reduced price of $3.866 per share, purchasing an aggregate of 854,002 shares. In consideration, SeaStar Medical will issue new unregistered Series A and Series B warrants exercisable for up to an aggregate of 1,708,004 shares of common stock, with an exercise price of $3.616 per share and varying terms. The net proceeds are intended for general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.

SeaStar Medical Holding Corp. reported a net loss of $3.73 million for the second quarter of 2026, an increase from $2.00 million in the prior year. The company issued a going concern warning, stating that its current cash of $6.96 million is insufficient to fund operations for the next 12 months. Despite a significant 82% increase in net revenue to $0.62 million for the quarter, operating expenses, particularly R&D, also rose sharply. The company continues to advance its medical device technology, including its FDA-approved QUELIMMUNE product and a pivotal clinical trial for adult SCD.

SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase year-over-year, driven by increased demand for its QUELIMMUNE therapy. The company's net loss widened to $3.7 million, or $0.91 per share, compared to a net loss of $2.0 million, or $1.77 per share, in Q2 2025. Key business advancements include adding three new children's hospitals to its QUELIMMUNE customer base, advancing enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and obtaining ICD-10-PCS codes for its SCD therapy.

SeaStar Medical reported Q2 2026 net revenue of $0.6 million, an 82% increase year-over-year, driven by expanded use of its QUELIMMUNE therapy in pediatric acute kidney injury (AKI). The company also significantly advanced enrollment in its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, reaching 223 of 339 patients. Additionally, SeaStar Medical obtained ICD-10-PCS codes for its Selective Cytopheretic Device (SCD) therapy, enabling standardized inpatient hospital billing. The net loss for the quarter was $3.7 million.

SeaStar Medical Holding Corporation announced it will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. The company will host a webcast and conference call on the same day at 4:30 p.m. ET to discuss the results and business progress. Preregistration is required for the live call.

SeaStar Medical Holding Corporation announced its sponsorship of key initiatives to advance the treatment of pediatric acute kidney injury (AKI). The company is sponsoring the KidneyBee Summit 2026 and hosting an educational webinar on August 11, 2026, focusing on its QUELIMMUNE® (SCD-PED) therapy. QUELIMMUNE, approved in February 2024, has shown a 77% survival rate in clinical trials and 76% in real-world data for critically ill pediatric patients with AKI.

SeaStar Medical Holding Corporation's Compensation Committee approved retention bonuses for executives Eric Schlorff and Kevin Chung. The bonuses, totaling $200,000 for Schlorff and $140,000 for Chung, will vest in three installments on July 1, 2026, November 1, 2026, and March 1, 2027. Each payment includes an additional 25% in common stock, subject to continued employment. These bonuses are part of a wider retention program for the company's long-serving employees.

SeaStar Medical Holding Corporation announced that it entered into a separation and release agreement with Mr. Green on June 10, 2026. This agreement resolves all claims related to his previously disclosed not-for-cause termination. Under the terms of the mutual resolution, SeaStar Medical has agreed to pay Mr. Green an amount greater than what was initially disclosed in the August 19, 2025 8-K filing.

SeaStar Medical Holding Corporation announced that its Selective Cytopheretic Device (SCD) therapy, QUELIMMUNE, has received dedicated ICD-10-PCS codes from the Centers for Medicare & Medicaid Services (CMS). These codes will enable standardized administrative, billing, and statistical reporting for the therapy's use in inpatient hospital settings for acute kidney injury (AKI) patients requiring renal replacement therapy. This development is expected to significantly ease logistics for existing customers and pave the way for broader adoption, particularly in the adult AKI market, which is estimated to be approximately $4.5 billion. The new codes are set to take effect on October 1, 2026.

SeaStar Medical Holding Corporation announced that its Chief Executive Officer, Eric Schlorff, will present at the Virtual Investor Summit Conference on June 24th at 10:30 am ET. The presentation will be available live online, with a replay accessible on the company's website for 30 days. SeaStar Medical is a commercial-stage healthcare company with an FDA-approved product, QUELIMMUNE®, and an ongoing pivotal clinical trial for adult Acute Kidney Injury.